Passage of HIV-1 Molecular Clones into Different Cell Lines Confers Differential Sensitivity to Neutralization  by Zhang, Yi-jun et al.
VIROLOGY 238, 254–264 (1997)
ARTICLE NO. VY978812
Passage of HIV-1 Molecular Clones into Different Cell Lines
Confers Differential Sensitivity to Neutralization
Yi-jun Zhang,* Robert Fredriksson,* Jane A. McKeating,† and Eva Maria Fenyo¨*,1
*Microbiology and Tumorbiology Centre, Karolinska Institute, 171 77 Stockholm, Sweden; and †School of Animal and Microbial Sciences,
University of Reading, Whiteknights, Reading, RG6 2AJ, United Kingdom
Received February 27, 1997; returned to author for revision March 25, 1997; accepted September 2, 1997
In this study, progeny viruses of four HIV-1 molecular clones were tested for sensitivity to neutralization following
prolonged passage in peripheral blood mononuclear cells (PBMC) and MT-2, H9, and CEM T-lymphoid cell lines. Two of
the viruses were able to establish persistent infection with no cytopathic effect in H9 and CEM cells. Such adaptation
conferred increased sensitivity to neutralization by a panel of human sera obtained from HIV-1-infected asymptomatic
individuals, by soluble CD4 and by monoclonal antibodies directed to a linear epitope in the V3 region (268-D) and a
conformational epitope in the CD4 binding site of the envelope gp120 (1.5e). Increased sensitivity to neutralizatiom was
paralleled by increased binding of these mAbs to native envelope glycoproteins and by increased binding capacity to CD4
expressed on the cell surface. Our results show that virus–host cell interactions are important in influencing sensitivity to
neutralization of HIV-1. In primary PBMC or in cytopathic interactions in cell lines, like in MT-2 cells, envelope epitopes
important for neutralization remain masked. In contrast, noncytopathic but productive virus–host cell interactions may lead
to an increased exposure of neutralizing epitopes and more efficient binding capacity to CD4 resulting in an increased
sensitivity to neutralization. q 1997 Academic Press
INTRODUCTION isolates thereby allowing selection of preexisting viral
populations during in vitro passage, such that the under-
The influence of host cell on the biological properties
lying molecular mechanism could not be determined
of human immunodeficiency virus type 1 (HIV-1) isolates
(Sawyer et al., 1994; Wrin et al., 1995). Host cell modifica-
when propagated in vitro has received much attention
tion of replicating virus may be a key event in HIV patho-recently (Cohen, 1993; Moore et al., 1993, 1995). The
genesis and elucidating its mechanism may help under-sensitivity to neutralization by human sera and by ligands
stand the pathogenic process.such as soluble CD4 (sCD4) and monoclonal antibodies
We previously isolated a number of molecular clones(mAbs) specific for the envelope glycoproteins has been
from a primary HIV-1 isolate passaged in PBMC (Fre-intensively investigated. In summary, there is a consen-
driksson et al., 1991; Tan et al., 1993). The parental virussus that primary HIV-1 isolates, that is, isolates subjected
isolate 4803 was able to infect cell lines and induceto a few short passages in peripheral blood mononuclear
syncytia in PBMC and was therefore classified as rapid/cells (PBMC), show varying sensitivity to neutralization
high phenotype (A˚sjo¨ et al., 1986; Fenyo¨ et al., 1988). Onlyby sera of HIV-1-infected individuals (Moore et al., 1995;
one of seven molecular clones yielded progeny virus withKostrikis et al., 1996; Nyambi et al., 1996; Weber et al.,
properties similar to the parental isolate (Fredriksson et1996). Passage of virus isolates in established T cell lines
al., 1991; Tan et al., 1993). The remaining clones yieldedselects for viruses which are sensitive to neutralization
viruses unable to replicate in the H9 and CEM cell lines(Sawyer et al., 1994; Wrin et al., 1995). Several authors
and induce syncytia in PBMC cultures and were classi-have suggested mechanisms to explain these observa-
fied as slow/low. More recently (McKeating et al., 1996),tions such that mutations occur within the env gene dur-
when using the MT-2 cell line, all clones were similar toing in vitro passage or that cell line dependent selection
the parental isolate in that they infected and inducedof the original quasispecies present within the primary
syncytia in MT-2 cells. However, these clonally derivedisolate occurs (Turner et al., 1992; Moore et al., 1993,
viruses had characteristics similar to primary isolates in1995; Mascola et al., 1994; Sullivan et al., 1995). Recent
that they were resistant to neutralization by sCD4, humanstudies reported experiments using nonclonal primary
HIV-1 seropositive sera, and a panel of mAbs specific
for epitopes including V2, V3, and multiple sites in the1 To whom correspondence and reprint requests should be ad-
CD4 binding region (McKeating et al., 1996). These clonaldressed at MTC, Box 280, Karolinska Institute, 171 77 Stockholm,
Sweden. viruses with ‘‘primary characteristics’’ provide a useful
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model system for determining the effect of host cell on Human sera, monoclonal antibodies, and recombinant
gp120 proteinthe biological properties of HIV-1.
Human sera were collected from HIV-1-infected
asymptomatic Swedish patients previously reportedMATERIALS AND METHODS
(McKeating et al., 1996). Neutralizing mAbs studied in-
clude 2.1H, 1.5e, and 39.13g specific for conformation-Cells and media
dependent gp120 epitopes overlapping the CD4 binding
site (Cordell et al., 1991; Ho et al., 1991); 268-D recogniz-Peripheral blood mononuclear cells from seronegative
ing a linear epitope within the V3 region (HIGPGR) (Gornyblood donors were prepared by Ficoll density gradient sep-
et al., 1989); and mAb 2G12 specific for a conformation-aration, activated with 2.5 mg/ml of phytohemagglutinin
dependent gp120 epitope (kindly provided by Dr. H. Kat-(PHA-P; Gibco) for 3 days in RPMI 1640 medium (Gibco)
inger) (Buchacher et al., 1994; Trkola et al., 1996). Poly-containing 10% inactivated fetal calf serum (FCS) and anti-
clonal rabbit serum against recombinant gp120 proteinbiotics (RPMI 10%). For virus passage, PHA-activated
of the HIV-1MN strain was kindly provided by Dr. PhillipPBMC were cultured in RPMI 10% supplemented with 10
W. Berman (Genentech, Inc.). Affinity-purified sheep poly-units of interleukin 2 (IL-2)/ml (Amersham) and 2 mg/ml
clonal antibody (D7324) recognizing a C-terminal ofpolybrene. HeLa cells were cultured in DMEM with 10%
gp120 epitope was purchased from Aalto BioreagentsFCS and antibiotics. The CD4-positive T cell lines H9, CEM,
(Dublin, Ireland). Soluble CD4 (sCD4) and purified recom-and MT-2 were cultured in RPMI 10% (Koot et al., 1992).
binant gp120 protein (HIV-1SF2 strain) produced in CHO
cells were obtained through the MRC AIDS Reagent Proj-
HIV-1 molecular clones and their passage/adaptation ect (NIBSC, Potters Bar, Hertfordshire, UK).
in different cells
Infectious dose-50 (ID50) titration and neutralizationFive micrograms of DNA of each of the four HIV-1
molecular clones (cl13, -31, -32, and -82) (Fredriksson et ID50 titration. Seventy-five-milliliter aliquots of virus su-
pernatants were diluted in medium with fivefold, eightal., 1991, Tan et al., 1993) was transfected into subcon-
fluent monolayers of HeLa cells in 12-well plates (Costar) steps dilutions in 96-well round-bottom plates (Costar)
as described previously (Zhang et al., 1994). Thereafter,using the lipofectamine (Gibco) technique as described
previously (McKeating et al., 1996). Forty-eight hours after an additional 75 ml of medium was added into each well
and incubated at 37C7 for 1 h. Subsequently, 105 PHAtransfection, HeLa cells were cocultivated with 3 1 106
activated PBMC or 2 1 106 MT-2 cells for 24 h. PBMC stimulated PBMC from two donors or, if cell line was
used, 2 1 104 cells from each cell line were added toand MT-2 cells were then recovered, washed, and further
cultured. At day 3 freshly activated PBMC and uninfected each well. The plates were washed at days 1 and 3,
respectively, by centrifugation and medium change. AtMT-2 cells were added. Supernatants from both PBMC
and MT-2 cultures were collected when p24 antigen val- day 7, 100 ml of culture supernatant was analyzed in an
in-house HIV-1 p24 antigen capture ELISA (Sundqvist etues were over 2 ng/ml and used as first-passage virus
stocks. One-milliliter aliquots of these virus stocks were al., 1989). The ID50 was defined as the reciprocal of the
virus dilutions resulting in 50% of the positive wells forused to infect PBMC and MT-2 cells, respectively, for an
additional two passages. Supernatants collected at third virus p24 antigen production (Reed-Muench calculation).
Neutralization assay. Sera were inactivated at 567 forpassage level are designated ‘‘early passage virus.’’ Two-
milliliter aliquots of the first-passage virus stocks pro- 30 min and subsequently diluted in medium in twofold
dilution steps, starting from 1:10. Thirty ID50 of pretitratedduced in PBMC were used to infect 6 1 106 PBMC,
followed by cocultivation with 3 1 106 H9 or CEM cells virus supernatants in 75 ml were added into each well
and incubated at 377 for 1 h and cells were added. Platesat day 7. Cocultures were split twice a week to maintain
a cell concentration of 1 1 106 cells/ml. Early passage were washed as mentioned above and at day 7, 100 ml
of supernatants was tested in an in-house HIV-1 p24virus was collected from these cultures after 3 weeks to
match the early passage virus from PBMC and MT-2 antigen capture ELISA. Neutralizing titers were defined
as the reciprocal of the highest dilutions of serum, mAb,cells. Subsequently, all cultures were maintained for an
additional 8 weeks to conform with the study of Wrin and or sCD4 giving an absorbance value (mean of duplicate
wells) below the cutoff value for HIV-1 p24 antigen cap-colleagues (1995). Uninfected PBMC and MT-2 cells had
to be added twice a week to PBMC and MT-2 cultures, ture ELISA assay. In each plate, five wells with virus only
were included to check the efficiency of washing, fiverespectively. At the end of this period, culture medium
was changed 2 days before collection of supernatants, wells with cells only were included as negative control,
and five wells with both virus and cells were includedtermed ‘‘late passage virus.’’ All virus stocks were sub-
jected to low speed centrifugation and frozen at 0707. as positive controls. The cutoff absorbance value for neu-
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TABLE 1tralization was 0.2–0.25 above the background which
corresponds to more than 90% reduction in viral antigen Replicative and Syncytium-Inducing Capacity
compared with positive virus control. Neutralization of Early Passage Viruses
assays were not evaluated if the mean absorbance val-
Passage inues of the positive controls were less than five times the
cutoff of the HIV-1 p24 antigen capture ELISA.
PBMC MT-2 cells H9 cells CEM cells
Quantitation of gp120 envelope protein in virus stocks
Virus Repla Syncb Repl Sync Repl Sync Repl Sync
Sheep polyclonal antibody D7324 recognizing a con-
CL13 / 0 / // 0 0 0 0served epitope at the COOH terminus of gp120 (Aalto
CL31 / 0 / // 0 0 0 0Bioreagents) was coated onto 96-well plates (Nunc, Inter
CL32 / / / // / / / /
Med) at a concentration of 50 ng/ml at 47 overnight. CL82 / 0 / // / 0 0 0
Plates were washed six times with PBS buffer containing
a Repl, replication: 0, 0.2 ng/ml p24 antigen production over a0.5 M NaCl and 0.1% Tween 20 (Sigma) and blocked with
period of 3 weeks; /, three sequential increasing values (0.2–2 ng/1% BSA (Sigma) in PBS for 2 h at 377. After being washed,
ml) of p24 antigen.100 ml supernatant of virus stocks was added to the b Sync, syncytia:0, no apparent syncytia formation; /, large syncytia
wells and incubated at 377 for 1.5 h. Recombinant gp120 apparent in every field; //, extensive syncytia formation in every field,
protein was diluted in PBS and used for the standard uninfected cells had to be added to keep the culture alive.
curve. Rabbit anti-HIV-1MN gp120 serum diluted at 1:1000
in PBS containing 20% sheep serum (Sigma) was added
cells were incubated with 200 ml of FITC-conjugatedfollowed by a sheep anti-rabbit horseradish peroxidase-
(1:20) rabbit anti-human IgG (g-chains), followed byconjugated antibody (Sigma). Assays were developed by
washing, and finally fixed by 1% paraformaldehyde inaddition of substrate O-phenylenediamine dihydrochlo-
PBS. Cell populations were analyzed by FACScan andride (OPD) (Sigma) and the absorbance measured at 490
the data were processed by using CellQuest softwarenm. The gp120 protein concentrations were calculated
program (Becton Dickinson, U.S.A.).by comparison with the standard curve and expressed
in nanograms per milliliter.
Nucleotide sequencing
MAb binding assay Late passage virus from MT-2 and H9 cells was used
to infect MT-2 and H9 cells, respectively. DNA samplesThe binding of mAbs to the native form of viral gp120
proteins was measured by ELISA as described above. were prepared from 21 106 infected cells, PCR amplified
with nested primers (outer primer set: JA9 5*CAC AGTIn order to use the native form of the envelope protein,
virus stocks (without inactivation by detergent) were di- ACA ATG TAC ACA TG 3 *; JA12 5*ACA GTA GAA AAA
TTC CCC TC3 *. inner nested primer set: JA10 5*AAA TGGluted according to the pretitrated gp120 concentration
and a saturating amount of gp120 (0.7 mg/ml) was added CAG TCT AGC AGA AG 3 *; JA53 5*AAT TTC TGG GTC
CCC TCC TG 3 *) specific for the V3 region of the enve-to the plates precoated with the D7324 antibody. To en-
sure that saturating amounts of gp120 were used, un- lope gene (Albert and Fenyo¨, 1990). Amplified PCR prod-
ucts were cloned into pBluescript plasmid (Stratagene)bound gp120 was determined after absorption. The
amount of excess gp120 was similar for all wells (about and the V3 region of one clone from each cell line was
sequenced by using the T7 sequencing kit (Pharmacia).0.05 mg/ml) and residual infectious virus was barely de-
tected (ID50 on MT-2 cells 501). After incubation, and
washing of excess unbound gp120, increasing concen- RESULTS
trations of mAbs were added to duplicate wells. Bound
Biological properties of viruses recovered after short-
mAbs were visualized using an anti-human IgG mono-
term and long-term passage in PBMC and cell lines
clonal antibody conjugated to horseradish peroxidase
and OPD substrate. PBMC and MT-2 cells could support replication of all
four clonally derived viruses. Infection was first detected
Detection of virus binding to MT-2 cells 6 days after cocultivation with transfected HeLa cells and
extracellular p24 antigen was greater than 2 ng/ml byAliquots of virus stocks (0.4 ml) containing similar
amounts of infectious virus (503.6 and 503.5 ID50 for MT-2 days 12 and 8, respectively. In subsequent passages,
supernatants were regularly collected 7 days postinfec-and H9-passaged virus, respectively) were incubated
with 0.25 1 106 MT-2 cells for 0, 10, 30, and 60 min at tion. MT-2 cultures showed syncytia formation leading
to extensive cell death within several days such that47. The cells were washed two times with cold RPMI
1640 medium and incubated with 200 ml of monoclonal uninfected MT-2 cells had to be added to maintain cul-
ture viability (Table 1). This pattern of cytopathogenicityantibody 268-D or 1.5e at 10 mg/ml. After being washed,
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TABLE 2 MT-2 cultures. When tested on PBMC, late passage cl32
from H9 and CEM cells had a reduced replicative capac-Replicative Capacity of Late Passage cl32 in Different Host Cells
ity. In addition, virus harvested from CEM cells had a
Passage in reduced replicative capacity in H9 cells (Table 2). These
data show that progeny virus from closely related clones
Titration in PBMC MT-2 H9 CEM may behave differently on different cell lines with regard
to the capacity to replicate and induce syncytia.PBMC 2.4a 3.1 0.2 2.6
MT-2 2.6 3.4 3.3 2.4
Neutralization of early passage virusesH9 2.3 3.1 2.7 0.4
Viruses derived from the transfection of HeLa cellsa Log 5 ID50 titers.
were passaged three times in PBMC and MT-2 cells and
the extracellular virus collected as early passage virus
stocks. These ‘‘early passage’’ viruses were tested fordid not change over time, in that, even after 3 months of
passage, all four clonally derived viruses from infected sensitivity to neutralization by sera from 10 HIV-1-infected
asymptomatic individuals, the human mAb 2G12, andMT-2 cell cultures induced syncytia in MT-2 cells. Using
other cell systems, clone 32 could be distinguished from sCD4 using either the MT-2 cell line or PBMC as target
cells. Virus passaged either in PBMC or in MT-2 cellsthe other clones in that only cl32 was able to induce
large syncytia in PBMC cultures and to productively infect was resistant to neutralization by sCD4 even when
amounts up to 100 mg/ml were used (Table 3). All virusesCEM and H9 cells (Table 1). Syncytia were observed in
cl32-infected H9 and CEM cells 10 days after cocultiva- were neutralized by mAb 2G12 at a final concentration
of 25 mg/ml. Eight of ten human sera showed low titertion with infected PBMC but disappeared within 3 weeks
thereafter. Interestingly, these cultures survived without neutralizing activity against these viruses. MT-2 or PBMC
passaged viruses showed similar sensitivity to neutral-the addition of uninfected cells. Late passage cl32 har-
vested from H9 cells was, however, still cytopathic for ization, with slight variation in titres between 1:20 and
1:80. When PBMC were used as targets, serum neutraliz-both H9 and MT-2 cells. Both cultures produced similar
amounts of infectious virus (53.5 and 53.6 ID50 , respec- ing titers were similar to those obtained for MT-2 cells
(Table 4). It should be noted that ID50 titers of virus stockstively) but supernatants from H9 cultures had a 15.5-fold
higher gp120 concentration indicating that H9 cultures showed similar ranges of variation for infection of PBMC
and MT-2 cells. Notably, the ID50 titer range for PBMCproduced more infectious particles or excess gp120 than
TABLE 3
Sensitivity of Early Passage Viruses to Neutralization in MT-2 Target Cellsa
Passage in
PBMC MT-2 cells
Neutralization with CL13 CL31 CL32 CL82 CL13 CL31 CL32 CL82
HIV-1/ human sera
1 20b 20 80 20 0 20 20 20
3 0 20 80 20 0 80 80 20
4 20 20 20 20 0 80 20 0
5 0 0 0 0 0 0 0 20
6 0 0 0 0 0 0 20 0
7 20 20 80 0 0 20 20 0
8 0 0 0 0 0 0 0 0
9 80 0 20 0 20 0 0 0
10 0 0 0 0 0 0 0 0
11 0 20 80 20 0 20 20 20
Ligands
2G12 (25 mg/ml) / / / / / / / /
sCD4c (100 mg/ml) 0 0 0 0 0 0 0 0
a Supernatant harvested at third passage level. Viruses were titrated on MT-2 cells and 30 ID50 was used in the neutralization assay. The results
of one of two experiments are shown.
b Reciprocal neutralizing titers; 0, 20.
c The laboratory strains HIV-1MN and HIV-1IIIB were readily neutralized with 1–5 mg/ml sCD4.
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TABLE 4
Sensitivity of Early Passage Viruses to Neutralization in PBMC Target Cellsa
Passage in
PBMC MT-2 cells H9 cells
Neutralization with CL13 CL31 CL32 CL82 CL13 CL31 CL32 CL82 CL32
HIV-1/ human sera
1 20b 20 80 20 20 20 80 20 80
3 20 20 80 80 0 80 80 20 80
4 0 80 20 20 20 80 80 20 40
5 0 0 20 0 0 20 20 0 0
6 20 0 80 0 0 0 80 0 40
7 0 0 20 20 20 20 20 0 0
8 0 0 0 0 0 0 0 0 0
9 80 0 20 0 80 0 0 0 20
10 0 0 0 0 0 0 0 0 0
11 20 20 20 20 0 20 20 20 20
Ligands
2G12 (25 mg/ml) / / / / / / / / /
sCD4c (100 mg/ml) 0 0 0 0 0 0 0 0 50
a Supernatant harvested at third passage level. Viruses were titrated on PBMC and 30 ID50 was used in the neutralization assay. The results of
one of two experiments are shown.
b Reciprocal neutralizing titers; 0, 20.
c The laboratory strains HIV-1MN and HIV-1IIIB were readily neutralized by 1–5 mg/ml sCD4.
passaged viruses was 503.2 to 504.4 and 502.6 to 504.4, being nearly 25-fold. Clearly, much less virus was used
in the PBMC assay than in the MT-2 assay and thiswhereas for MT-2 passaged viruses it was 503.6 to 504.8
and 503.2 to 505.2 when tested in PBMC and MT-2 cells, could have resulted in higher serum neutralizing titers.
In contrast, an increased sensitivity to neutralizationrespectively. These data show that three passages, re-
gardless of cell type, do not consistently alter the replica- could not be observed with MT-2 passaged viruses and
their resistance to neutralization by sCD4 was main-tive capacity of these clonally derived viruses and their
sensitivity to neutralization by human sera or sCD4. Fur- tained. Similarly, long-term PBMC passage did not
change the sensitivity of cl32 to neutralization.thermore, use of PBMC or the MT-2 cells as targets for
the neutralization assay does not influence the outcome We previously reported that cl32 and cl82 could not
be neutralized by a panel of mAbs to V2, V3, and theof neutralization.
CD4 binding site (CD4bs) of the HIV-1 envelope gp120
Neutralization of late passage viruses (McKeating et al., 1996). We selected a number of these
mAbs to evaluate their ability to neutralize late passageIn these experiments, viruses were carried for 3
virus. Both cl32 and cl82 passaged in H9 cells weremonths in PBMC, MT-2, H9, and CEM cells, respectively.
sensitive to neutralization by mAbs 268-D, 1.5e, andLate passage cl32 from H9 cells was neutralized at se-
39.13g but not by 2.1H (Table 6). The results indicate thatrum titers up to 100-fold higher and at sCD4 concentra-
long-term passage of clonally derived viruses in the H9tions up to 70-fold lower than early passage cl32 (Table
cell line results in variants with increased sensitivity to5). This increased sensitivity to neutralization could be
neutralization by mAbs to distinct nonoverlapping epi-detected regardless of the target cell used, MT-2 or H9, in
topes. Such increased sensitivity to neutralization is cellthe neutralization assay. That long-term passage indeed
type dependent and does not occur per se upon passageincreased sensitivity to neutralization was further con-
in all established cell lines.firmed by passage of cl82 in H9 cells and cl32 in CEM
cells. However, in the case of CEM passaged cl32, the
Monoclonal antibody binding to the native form of
target cells used in the neutralization assay appeared to
envelope glycoproteins derived from late passage
play a decisive role in determining the neutralization ti-
viruses
ters of sera, in that titers were up to 64-fold higher in
PBMC than in MT-2 target cells. This difference may be In order to investigate the possible mechanism re-
sponsible for the differential sensitivity of late passageexplained by the fact that CEM passaged cl32 was more
infectious for PBMC than for MT-2 cells, the difference viruses, the binding capacity of human mAbs 268-D and
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TABLE 5
Sensitivity to Neutralization of Late Passage Virusesa
Target cells used in neutralization
MT-2 cells H9 cells PBMC
Neutralization with 32P 13M 31M 32M 82M 32C 32H 82H 32H 32C
HIV-1/ human sera
1 20b 0 0 0 0 80 1280 640 5120 2560
3 80 0 20 20 20 160 2560 640 640 5120
4 40 0 0 0 0 160 1280 1280 2560 5120
5 0 0 0 0 0 40 640 160 1280 1280
6 40 0 0 0 0 80 1280 640 2560 1280
7 80 0 0 0 0 320 640 320 1280 5120
9 0 20 0 0 0 20 80 80 80 1280
11 40 0 0 20 0 320 640 640 1280 1280
Ligands
2G12 (25 mg/ml) / / / / / / / / / /
sCD4c (mg/ml) 50 0 0 100 100 12 3 1.5 1.5 6
Log 5 ID50 titers 2.1 3.3 3.1 3.4 3.3 2.4 3.3 2.3 2.7 4.3
a Late passage viruses were obtained from PBMC (P), MT-2 (M), CEM (C), and H9 (H) cells as described in the text. 30 ID50 of virus was used
in neutralization based on ID50 titration in each individual target cell. The results of one of two experiments are shown.
b Reciprocal neutralizing titers; 0, 20; repeated experiment with 32H and 32M in serum neutralization resulted similar titers.
c The laboratory strains HIV-1MN and HIV-1IIIB were readily neutralized by 1–5 mg/ml sCD4.
1.5e showing differential neutralizing capacity was mea- Virus binding to CD4 expressed on the surface of
MT-2 cellssured against native viral envelope proteins derived from
MT-2 and H9 cells. For the sake of comparison, constant Using the mAb 268-D, binding of late passage virus from
saturating amounts of gp120 protein were used. An in- H9 cells showed a time-dependent increase, whereas no
creased binding capacity was observed with mAbs 268- binding could be detected with late passage virus from
D and 1.5e on gp120 derived from H9 cells compared to MT-2 cells, even after 60 min of incubation (Figs. 2A and
gp120 derived from MT-2 cells (Fig. 1). The increased 2B, respectively). As expected, cell surface bound virus
ability of these mAbs to recognize H9-derived gp120 ap- could not be detected by mAb 1.5e, since the CD4 binding
peared to be consistent with their capacity to neutralize site on gp120 was blocked and not available to the anti-
the H9-adapted viruses. body (data not shown). To test whether the binding de-
tected with mAb 268-D reflected the binding of virus-asso-
ciated gp120, MT-2 cells were lysed at the 60 min timeTABLE 6
point with 0.5% Triton X-100 and the p24 and gp120 anti-Sensitivity of Late Passage Viruses to Neutralization
gen contents measured. Cell lysates incubated with lateby Monoclonal Antibodiesa
passage virus from H9 cells contained 2 ng p24/ml,
Passage in whereas cell lysates treated with virus from MT-2 cells
contained 0.24 ng p24/ml. Similarly, there was a 14-fold
H9 cells MT-2 cells
difference in gp120 content of cell lysates. The resultsMonoclonal
indicate that our assay indeed detected binding of virusantibody CL32 CL82 CL32 CL82
particles (and not only free gp120) and that late passage
268-Db 1.5 3 100 100 virus from MT-2 cells binds less efficiently to CD4 present
1.5eb 3 0.3 50 50 on the cell surface than virus passaged in H9 cells. Thus
2.1Hb 50 50 50 50
passage in H9 cells increases the binding capacity to2G12b 1.5 3 3 12
CD4 and renders the virus sensitive to neutralization by39.13gc 160 1280 40 40
sCD4 as well as some mAbs.
a Late passage viruses were titrated on MT-2 cells and 30ID-50 of
Nucleotide sequencing of HIV-1 V3 loop derived fromvirus was used in the neutralization assay.
b Figures denote antibody concentrations (mg/ml) needed for virus passage in different cell types
neutralization.
Since monoclonal antibody 268-D recognizing a linearc Figures denote reciprocal serum dilutions needed for virus neutral-
ization. epitope in the V3 region showed differential neutralizing
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FIG. 1. Mabs 268D (A) and 1.5e (B) binding to native gp120 of late passage viruses CL32 and CL82 derived from passage in MT-2 (M) and H9
(H) cells, respectively. Binding activity was expressed as absorbance values obtained at different antibody concentrations. The absorbance values
represent the mean of two experiments.
capacity to clones derived from passage in MT-2 and H9 the virus stocks are prepared. Using progeny viruses
of molecular clones we show that the virus–host cellcells, the V3 loop including the epitope (HIGPGR) was
interaction may result in a balance between virus replica-sequenced. With the exception of cl82/MT-2 (G/K) which
tion and host cell survival. Cl32 in H9 and CEM cells andremained resistant to neutralization, no amino acid
cl82 in H9 cells were able to undergo such an adaptationchanges were observed in the V3 region from cl32 and
after prolonged time of passage and the viruses showedcl82 virus passaged in either H9 or MT-2 cells (Fig. 3).
an altered cell tropism concomitant with an increasedThese data suggest either that changes outside the region
sensitivity to neutralization by human sera and sCD4. Thesequenced were responsible for the observed phenotype
results also show that adaptation confered an increasedor that factors other than the primary sequence were in-
binding capacity to CD4. However, prolonged passagevolved in conferring altered sensitivity to neutralization.
alone without adaptation, like in MT-2 cells or PBMC,
did not lead to an increased sensitivity to neutralization.DISCUSSION
Likewise, short-time in vitro passage of clonally derived
In the present study we show that sensitivity of HIV-1 viruses in various T cell lines did not change the pattern
of virus neutralization.to neutralization is dependent on the host cell in which
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FIG. 2. Histogram overlay of cells incubated with medium alone or with late passage cl32 from H9 cells (A and C) or MT-2 cells (B and D) at
time points indicated. The detecting antibodies 268-D (A and B) or 1.5e (C and D) were used at 10 mg/ml.
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FIG. 3. Deduced amino acid sequences of V3 region from late passage viruses derived from passage in MT-2 (CL32/MT-2, CL82/MT-2) and H9
(CL32/H9, CL82/H9) cells, respectively. Sequences are aligned to the sequence of CL32 not subjected to in vitro passage. Identity is indicated by
a dash; departures are indicated by the single letter amino acid codes.
Sawyer and colleagues reported that three passages of data indicate that binding to the oligomeric form of the
envelope protein might be used as a marker for anti-HIV-primary HIV-1 isolates in H9 cells rendered the viruses
sensitive to neutralization by human sera (Sawyer et al., 1 antibodies with potential neutralizing activity (Parren et
al., 1996). Furthermore, the increased binding of 1.5e1994). In contrast, Wrin and colleagues (1995) reported that
such a phenotypic change only occurred after prolonged and 268-D antibodies to the late passage viral envelope
gp120 suggests that the V3 loop as well as part of thepassage and adaptation. Such differences may reflect dif-
ferential selection and adaptation of different primary iso- CD4bs was masked in early passage viruses. However,
adaptation in T cell lines, such as in H9 cells, allowslates in the H9 cell line. It is also interesting to note that
in the latter study, changes in neutralization were coinci- increased exposure of neutralizing epitopes rendering
the virus more sensitive to neutralization. Whether suchdent with reduced cytopathogenicity of the late passage
virus in H9 cells. However, our data show that late passage an alteration could also explain the differential sensitivity
to antibody neutralization against HIV-1 primary isolatescl32 from H9 and CEM cells was as cytopathogenic in
MT-2 cells as early passage virus. Nevertheless, there remains to be investigated (Kostrikis et al., 1996; Nyambi
et al., 1996; Weber et al., 1996).was a difference in cell tropism, in that late passage cl32
showed a reduced replicative capacity in PBMC and H9 Several mechanisms underlying the increased expo-
sure of neutralizing epitopes in association with T cellcells, respectively (Table 2). Our data are in line with previ-
ous observations that passage in different cell lines may line adaptation of a virus have been considered. In one
study, increased sensitivity to neutralization of JR-CSFexert a differential influence on the biological properties
of viruses (Cheng-Mayer et al., 1991; Peden et al., 1991). virus was associated with a single amino acid change
in the V3 region of the envelope. The change resulted inPassage of the HIV-1LAI molecular clone in SupT1 cells
conferred a more restricted cell tropism, whereas passage increased accessibility of the epitope within the oligo-
meric complex (Bou-Habib et al., 1994). Interestingly, ex-of the HIV-1SF2 molecular clone in HUT78 cells resulted in
a broad host cell tropism (Cheng-Mayer et al., 1991; Peden posure of epitopes in the V3 loop could be further en-
hanced in T cell line adapted viruses through binding ofet al., 1991). We now further extend these observations
and show that passage and adaptation of HIV-1 molecular sCD4 and a comformational change of envelope gp120
has been proposed to be responsible for this processclones in different host cells may affect not only their repli-
cative capacity but also their sensitivity to neutralization (Stamatatos and Cheng-Mayer, 1995; Sullivan et al.,
1995). In our experiments, however, the amino acid se-(Table 5).
We found that H9-adapted viruses showed an in- quence of the linear epitope within the V3 loop recog-
nized by mAb 268-D remained unchanged (Fig. 2). More-creased sensitivity to neutralization and this was associ-
ated with an increased binding capacity of mAbs 1.5e over, it is unlikely that amino acid substitutions in regions
outside the binding site of mAb 268-D change the confor-and 268-D directed to both linear and conformational
epitopes within gp120 (Table 6). Since our binding assay mation of envelope gp120, since similar amounts of the
mAb 2G12, directed against a conformational epitope inmeasures, at least in part, the binding activity to oligo-
meric envelope gp120, our results are in line with those gp120 other than the CD4bs, neutralized both H9 and
MT-2 passaged viruses (Table 6). Another possibilityof others showing a correlation between the ability of
antibody to bind the oligomeric envelope glycoprotein at might be the altered glycosylation of envelope proteins
following passage and adaptation in cell lines. Differentthe cell surface and their ability to neutralize viral infectiv-
ity (Fig. 1) (Sattentau and Moore, 1995; Sullivan et al., cell types or individual cell lines may show different gly-
cosylation patterns (Goochee and Monica, 1990) and1995; Fouts et al., 1997). It is also interesting to note that
antibody 2.1H, which showed no differential binding, also may conceivably result in viruses with altered envelope
properties. Indeed, glycosylation of HIV-1 envelope pro-failed to neutralize the clones (Table 6). Together, these
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tein has been shown to influence both the virus infectivity like in PBMC and MT-2 cells where no adaptation occurs,
neutralizing epitopes in the viral envelope remainand immunogenicity (Benjouad et al., 1992; Lee et al.,
1992). A recent report suggested that differential enve- masked. It is intriguing that virus–host cell interactions
appear to have a decisive role in determining sensitivitylope glycosylation was responsible for the observed dif-
ferences in neutralization sensitivity of viruses derived to neutralization. When designing neutralization assays
for use in vaccine studies, the viral phenotype, as re-from macrophages and PBMC (Willey et al., 1996). Simi-
larly, propagation of HIV-1 in T cell lines or in vitro selec- flected by the replicative capacity and cytopathogenicity
of HIV-1 isolates should be taken into consideration intion by neutralizing mAbs may induce changes in enve-
lope glycosylation that may affect both the tropism and relation to the cell type used.
the neutralization sensitivity (Cheng-Mayer et al., 1991;
Back et al., 1994; Schonning et al., 1996). However, the ACKNOWLEDGMENTS
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